Dose and duration-dependence of ganciclovir treatment against murine cytomegalovirus infection in severe combined immunodeficient mice

Antiviral Research

Volumn 39, Issue 3, 1998, Pages 189-197

  Duan, Jianmin ^a   Paris, William ^a   Kibler, Philip ^a   Bousquet, Christiane ^a   Liuzzi, Michel ^a   Cordingley, Michael G ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

Cytomegalovirus; Dose response; Ganciclovir; SCID mice

Indexed keywords

GANCICLOVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEATH; DOSE RESPONSE; DRUG TOXICITY; FEMALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VIRUS REPLICATION; VIRUS TITRATION; WASTING SYNDROME;

ANALYSIS OF VARIANCE; ANIMALS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GANCICLOVIR; IMMUNOCOMPROMISED HOST; MICE; MICE, SCID; MUROMEGALOVIRUS;

ANIMALIA; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; MAIZE CHLOROTIC MOTTLE VIRUS; MOUSE CYTOMEGALOVIRUS 1; MURINAE;

EID: 0032190932     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(98)00038-2     Document Type: Article

References (32)

1. Bosma G.C., Custer R.P., Bosma M.J. A severe combined immunodeficiency mutation in the mouse. Nature. 301:1983;527-530.
2. Bowden, R.A., 1993. Antivirals for cytomegalovirus. In: Michelson, S., Plotkin, S.A. (Eds.), Multidisciplinary Approach to Understanding Cytomegalovirus Disease. Elsevier, Amsterdam, pp. 241-249.
3. Braitman A., Swerdel M.R., Olsen S.E., Tuomari A.V., Blue J.S.L., Michalik T., Field A.K., Bonner D.P., Clark J.M. Evaluation of SQ 34514: pharmacokinetics and efficacy in experimental herpesvirus infections in mice. Antimicrob. Agents Chemother. 35:1991;1464-1468.
4. Bruggeman C.A. Cytomegalovirus and latency: an overview. Virchows Arch. B Cell. Pathol. Incl. Mol. Pathol. 64:1993;325-333.
5. Collier A.C., Corey L. Therapy of cytomegalovirus infections with ganciclovir: a critical appraisal. Curr. Clin. Top. Infect. Dis. (US). 12:1992;309-328.
6. DeAmond, B., 1991. Future directions in the management of cytomegalovirus infections. J. Acq. Imm. Def. Syn. 4 Suppl. 1, S53-S56.
7. Gerard L., Salmon-Ceron D. Pharmacology and clinical use of foscarnet. Int. J. Antimicrob. Ag. 5:1995;209-217.
8. Hsiung G.D., Chan V.F. Evaluation of new antiviral agents: II. The use of animal models. Antivir. Res. 12:1989;239-258.
9. Jabs D.A. Controversies in the treatment of cytomegalovirus retinitis: Foscarnet versus ganciclovir. Infect. Agents Dis. 4:1992;131-142.
10. Jacobson M.A. Current management of cytomegalovirus disease in patients with AIDS. AIDS Res. Human Retrovir. 10:1994;917-923.
11. Jordan M.C. Latent infection and the elusive cytomegalovirus. Rev. Inf. Dis. 5:1983;205-215.
12. Kern, E.R., 1991. Value of animal models to evaluate agents with potential activity against human cytomegalovirus. Transplant. Proc. 23 Suppl. 3, 152-155.
13. Markham A., Faulds D. Gancyclovir, an update of its therapeutic use in cytomegalovirus infection. Drugs. 48:1994;455-484.
14. Meyers, J.D., 1991. Critical evaluation of agents used in the treatment and prevention of cytomegalovirus infection in immunocompromised patients. Transplant Proc. 23 Suppl 3, 139-143.
15. Naesens L., Snoeck R., Andrei G., Balzarini J., Neyts J., De Clercq E. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their paharmacology and clinical potential in the treatment of viral infections. Antivir. Chem. Chemother. 8:1996;1-23.
16. Neyts J., Balzarini J., Naesens L., De Clercq E. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice. J. Med. Virol. 37:1992;67-71.
17. Neyts J., Stals F., De Clercq E. Activity of the anti-HIV agent 9-(2-phosphonyl-methoxyethyl)-2,6-diaminopurine against cytomegalovirus in vitro and in vivo. Eur. J. Clin. Microbiol. Infect. Dis. 12:1993;437-446.
18. Neyts J., Sobis H., Snoeck R., Vandeputte M., De Clercq E. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice. Eur. J. Clin. Microbiol. Infect. Dis. 12:1993;269-279.
19. Orellana J., Teicil S.A., Friedman A.H., Lerebours F., Winterkorn J., Mildvan D. Combined short- and long-term therapy for the treatment of cytomegalovirus retinitis using Gancyclovir (BW B759U). Ophthalmology. 94:1987;831-838.
20. Paul S., Dummer S. Topics in clinical pharmacology: gancyclovir. Am. J. Med. Sci. 304:1992;272-277.
21. Peters M., Timm U., Schurmann D., Pohle H.D., Ruf B. Combined and alternating ganciclovir and foscarnet in acute and maintenance therapy of human immunodeficiency virus-related cytomegalovirus encephalitis refractory to ganciclovir alone. Clin. Invest. 70:1992;456-458.
22. Polis M.A. Foscarnet and ganciclovir in the treatment of cytomegalovirus retinitis. J. Acquired Immune Defic. Syndr. 5(suppl.):1992;S3-S10.
23. Polis M.A., Masur H. Promising new treatments for cytomegalovirus retinitis. J. Am. Med. Assoc. 273:1995;1457-1459.
24. Reynolds R.P., Rahija R.J., Schenkman D.I., Richter C.B. Experimental murine cytomegalovirus infection in severe combined immunodeficient mice. Lab. Animal Sci. 43:1993;291-295.
25. Sasadeusz J.J., Sacks S.L. Systemic antivirals in herpesvirus infections. Dermatol. Ther. 11:1993;171-185.
26. Smee D.F., Burger R.A., Coombs J., Huffman J.H., Sidwell R.W. Progressive murine cytomegalovirus disease after termination of ganciclovir therapy in mice immunosuppressed by cyclophosphamide treatment. J. Infect. Dis. 164:1991;958-961.
27. Smee D.F., Morris J.B., Leonhardt J.A., Mead J.R., Holy A., Sidwell R.W. Treatment of murine cytomegalovirus infection in severe combined immunodeficient mice with ganciclovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, interferon, and bropirimine. Antimicrob. Agents Chemother. 36:1992;1837-1842.
28. Smee D.F., Sugiyama S.T., Reist E.J. Nucleotide analogs related to acyclovir and ganciclovir are effective against murine cytomegalovirus infection in BALB/c and severe combined immunodeficient mice. Antimicrob. Agents Chemother. 38:1994;2165-2168.
29. Smee D.F., Sugiyama S.T., Sidwell R.W., Barnett B.B. Effects of monoclonal antibody combined with ganciclovir or (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl] cytosine against murine cytomegalovirus infections in cell culture and in severe combined immunodeficient mice. Chemotherapy. 41:1995;141-148.
30. Snoeck, R., Neyts, J., De Clercq, E., 1993. Strategies for the treatment of cytomegalovirus infections. In: Michelson, S. and Plotkin S.A. (Eds.), Multidisciplinary Approach to Understanding Cytomegalovirus Disease. Elsevier, Amsterdam, pp. 269-278.
31. Winkler I., Winkelmann E., Scholl T., Rosner M., Jahne G., Helsberg M. Antiviral activity and pharmacokinetics of HOE 602, an acyclic nucleoside, in animal models. Antivir. Res. 14:1990;61-74.
32. Yang H., Drain R.L., Franco C.A., Clark J.M. Efficacy of BMS-180194 against experimental cytomegalovirus infection in immunocompromised mice. Antivir. Res. 29:1996;233-241.